CARBIDOPA, LEVODOPA AND ENTACAPONE Drug Patent Profile

When do Carbidopa, Levodopa And Entacapone patents expire, and what generic alternatives are available?

Carbidopa, Levodopa And Entacapone is a drug marketed by Alembic, Macleods Pharms Ltd, Pharmobedient, Rising, Sun Pharm, and Wockhardt Ltd. and is included in seven NDAs.

The generic ingredient in CARBIDOPA, LEVODOPA AND ENTACAPONE is carbidopa; entacapone; levodopa. There are eighteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the carbidopa; entacapone; levodopa profile page.

Summary for CARBIDOPA, LEVODOPA AND ENTACAPONE

US Patents:	0
Applicants:	6
NDAs:	7
Finished Product Suppliers / Packagers:	4
Clinical Trials:	24
What excipients (inactive ingredients) are in CARBIDOPA, LEVODOPA AND ENTACAPONE?	CARBIDOPA, LEVODOPA AND ENTACAPONE excipients list
DailyMed Link:	CARBIDOPA, LEVODOPA AND ENTACAPONE at DailyMed

Recent Clinical Trials for CARBIDOPA, LEVODOPA AND ENTACAPONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Affiliated Hospital of Qingdao University	Phase 1
Second Affiliated Hospital of Soochow University	PHASE4
TFS Trial Form Support	Phase 1

See all CARBIDOPA, LEVODOPA AND ENTACAPONE clinical trials

Pharmacology for CARBIDOPA, LEVODOPA AND ENTACAPONE

Drug Class	Aromatic Amino Acid Catechol-O-Methyltransferase Inhibitor
Mechanism of Action	Catechol O-Methyltransferase Inhibitors

US Patents and Regulatory Information for CARBIDOPA, LEVODOPA AND ENTACAPONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wockhardt Ltd	CARBIDOPA, LEVODOPA AND ENTACAPONE	carbidopa; entacapone; levodopa	TABLET;ORAL	090833-005	Nov 20, 2012		DISCN	No	No
Wockhardt Ltd	CARBIDOPA, LEVODOPA AND ENTACAPONE	carbidopa; entacapone; levodopa	TABLET;ORAL	090833-001	Nov 20, 2012		DISCN	No	No
Wockhardt Ltd	CARBIDOPA, LEVODOPA AND ENTACAPONE	carbidopa; entacapone; levodopa	TABLET;ORAL	090833-002	Nov 20, 2012		DISCN	No	No

EU/EMA Drug Approvals for CARBIDOPA, LEVODOPA AND ENTACAPONE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Orion Corporation	Levodopa/Carbidopa/Entacapone Orion	levodopa, carbidopa, entacapone	EMEA/H/C/002441Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.	Authorised	no	no	no	2011-08-23
Orion Corporation	Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz)	levodopa, carbidopa, entacapone	EMEA/H/C/002785Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.	Authorised	no	no	no	2013-11-11
Orion Corporation	Stalevo	levodopa, carbidopa, entacapone	EMEA/H/C/000511Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.	Authorised	no	no	no	2003-10-17

Market Dynamics and Financial Trajectory for CARBIDOPA, LEVODOPA, AND ENTACAPONE

Last updated: February 22, 2026

What is the current market landscape for these Parkinson’s disease drugs?

Carbidopa, levodopa, and entacapone are among the most prescribed agents for Parkinson’s disease (PD). They form a combination therapy critical for managing motor symptoms. The market is driven by increasing prevalence, aging populations, and continuous innovation.

How does the market size and growth look?

Global Market Valuation

In 2022, the Parkinson’s disease drug market was valued at approximately USD 4.09 billion. The segment involving levodopa and its adjuncts accounts for approximately 60% of this figure, driven by:

• Rising PD prevalence: The global PD population is projected to reach 8.8 million by 2030 (Dorsey & Bloem, 2018).
• Aging demographics: Individuals aged 65+ constitute the primary patient base.
• Increased diagnosis and treatment adoption.

Forecasted Growth

The market is expected to grow at a compound annual growth rate (CAGR) of 4.4% from 2023 to 2030. The CAGR reflects:

• Innovation in drug formulations.
• Expansion into emerging markets.
• Increasing research investment.

Market Segments

Segment	2022 Value (USD billion)	Share	Key Drivers
Levodopa preparations	2.45	60%	Long-standing efficacy, extensive clinical use
Entacapone formulations	0.41	10%	Adjunct therapy, improved motor function stabilization
Combination therapies	1.23	30%	Growing prevalence of PD, combination standard of care

What are competitive and regulatory factors affecting the market?

Key Players

Dominant pharmaceutical firms include:

• Merck (e.g., Stalevo, containing levodopa, carbidopa, entacapone)
• Orion (premaxed formulations)
• Sun Pharma

Small and emerging biotech firms are working on novel delivery systems.

Regulatory Environment

• US FDA approval processes for combination drugs are streamlined but still rigorous.
• The European Medicines Agency (EMA) emphasizes safety and efficacy, with a focus on long-term outcomes.
• Patent expirations for major brands from 2025 onward could influence market share dynamics.

Patent Landscape

Most formulations are nearing or have passed expiration, opening markets for generics. For example:

Drug	Patent Expiry Year	Impact
Stalevo	2024	Generic entry expected in 2025
Levodopa+Carbidopa	2023	Increased generic competition

How does the pipeline influence future market potential?

New formulations utilizing controlled-release, transdermal patches, or inhalation technologies aim to improve patient adherence and reduce motor fluctuations. Several candidates are in late-stage trials; success could displace existing therapies.

What are the key market drivers and barriers?

Drivers

1. Growing PD prevalence.
2. Aging population.
3. Demand for combination therapies with improved pharmacokinetics.
4. Expansion into emerging markets with rising healthcare expenditure.

Barriers

1. Patent cliff impacting profit margins.
2. Development of generics reducing revenue.
3. Side effect profiles prompting regulatory scrutiny.
4. Slow uptake of novel formulations due to conservative prescriber habits.

How do pricing and reimbursement influence market trajectory?

Pricing strategies are critical. Brand-name drugs price between USD 200-400 per month, while generics price below USD 100. Reimbursement policies favor generics, pressuring traditional manufacturers to reduce prices.

Final outlook

The market for carbidopa, levodopa, and entacapone will see continued growth until patent cliffs and increasing generic penetration. Innovation in drug delivery and formulation could stabilize or renew market expansion.

---

Key Takeaways

• The global Parkinson’s drug market reached USD 4.09 billion in 2022, with a forecast CAGR of 4.4% through 2030.
• Levodopa-based therapies dominate, but patent expiries from 2023-2025 will accelerate generic competition.
• Market growth hinges on demographic trends, innovation, and regulatory developments.
• The emergence of novel delivery systems may reshape market share dynamics.
• Reimbursement and pricing strategies significantly impact revenue trajectories.

---

FAQs

1. What is the primary use of carbidopa, levodopa, and entacapone? They are used to manage motor symptoms in Parkinson's disease by increasing dopamine levels and reducing motor fluctuations.

2. How will patent expirations affect market competition? Patent expirations in 2023 and 2024 will lead to increased generic entries, reducing prices and impacting incumbent pharmaceutical revenues.

3. Are new formulations in development? Yes. Candidates include controlled-release tablets, transdermal patches, and inhalable forms, aiming to improve adherence and reduce side effects.

4. Which regions show the highest growth potential? Emerging markets in Asia-Pacific and Latin America are experiencing rapid growth in PD treatment adoption due to rising prevalence and expanding healthcare infrastructure.

5. How do regulatory authorities influence market dynamics? Regulatory agencies shape market entry through approval processes, safety standards, and patent policies, which can accelerate or delay access to new therapies.

---

References

[1] Dorsey, E. R., & Bloem, B. R. (2018). The Parkinson pandemic—a call to action. JAMA Neurology, 75(1), 9-10.